Department of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0QQ, UK.
World J Urol. 2018 Dec;36(12):1891-1898. doi: 10.1007/s00345-018-2288-5. Epub 2018 Apr 21.
Genetic factors have been implicated in the pathogenesis of renal cell carcinoma (RCC), with around 3% of cases having a family history. A greater knowledge of the genetics of inherited RCC has the potential to translate into novel therapeutic targets for sporadic RCC.
A literature review was performed summarising the current knowledge on hereditary RCC diagnosis, surveillance and management.
Familial RCC is usually inherited in an autosomal dominant manner, although inherited RCC may present without a relevant family history. A number of familial RCC syndromes have been identified. Familial non-syndromic RCC is suspected when ≥ 2 relatives are affected in the absence of syndromic features, although clear diagnostic criteria are lacking. Young age at onset and bilateral/multicentric tumours are recognised characteristics which should prompt molecular genetic analysis. Surveillance in individuals at risk of inherited RCC aims to prevent morbidity and mortality via early detection of tumours. Though screening and management guidelines for some inherited RCC syndromes (e.g. von Hippel-Lindau disease, Birt-Hogg-Dube syndrome, hereditary leiomyomatosis) are well defined for rare cause of inherited RCC (e.g. germline BAP1 mutations), there is limited information regarding the lifetime RCC risks and the most appropriate screening modalities.
Increasing knowledge of the natural history and genetic basis has led to characterisation and tailored management of hereditary RCC syndromes. International data sharing of inherited RCC gene variant information may enable evidence-based improvements in the diagnosis, surveillance protocols and management of these rare conditions.
遗传因素已被牵涉到肾细胞癌(RCC)的发病机制中,约有 3%的病例有家族史。对遗传性 RCC 的遗传学有更深入的了解,有可能为散发性 RCC 转化为新的治疗靶点。
对遗传性 RCC 的诊断、监测和管理的现有知识进行了文献回顾。
家族性 RCC 通常以常染色体显性方式遗传,但遗传性 RCC 也可能没有相关的家族史。已经确定了一些家族性 RCC 综合征。当≥2 名亲属在没有综合征特征的情况下受到影响时,怀疑存在家族性非综合征性 RCC,但缺乏明确的诊断标准。发病年龄早和双侧/多中心肿瘤是应提示进行分子遗传学分析的特征。对遗传性 RCC 风险个体的监测旨在通过早期发现肿瘤来预防发病率和死亡率。虽然一些遗传性 RCC 综合征(如 von Hippel-Lindau 病、Birt-Hogg-Dube 综合征、遗传性平滑肌瘤病)的筛查和管理指南已经为遗传性 RCC 的罕见病因(如胚系 BAP1 突变)制定了明确的标准,但关于终生 RCC 风险和最适当的筛查方式的信息有限。
对自然史和遗传基础的了解不断增加,导致了遗传性 RCC 综合征的特征描述和针对性管理。遗传性 RCC 基因变异信息的国际数据共享可能会有助于改进这些罕见疾病的诊断、监测方案和管理。